Yasmine M. Abdel Aziz

Prof. Dr. Yasmine M. Abdel Aziz

Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt;
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
GLGehad Lotfy
Gehad Lotfy
MSMohamed M. Said
Mohamed M. Said
EAEl Sayed H. El Ashry
El Sayed H. El Ashry
EAEl Sayed H. El Ashry
El Sayed H. El Ashry
AAAbdullah Al-Dhfyan
Abdullah Al-Dhfyan
Assem BarakatAssem Barakat
Assem Barakat

1 March 2018 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
GLGehad Lotfy
Gehad Lotfy
EAEl Sayed H. El Ashry
El Sayed H. El Ashry
MSMohamed M. Said
Mohamed M. Said
EAEl Sayed H. El Ashry
El Sayed H. El Ashry
YAYasmine M. Abdel Aziz
Yasmine M. Abdel Aziz
Assem BarakatAssem Barakat
Assem Barakat

1 January 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Mohamed S. H. SalemMohamed S. H. Salem
Mohamed S. H. Salem
YAYasmine M. Abdel Aziz
Yasmine M. Abdel Aziz
MEMohamed S. Elgawish
Mohamed S. Elgawish
MSMohamed M. Said
Mohamed M. Said
KAKhaled A. M. Abouzid
Khaled A. M. Abouzid

24 December 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
REranza elrayess
ranza elrayess
YAYasmine M. Abdel Aziz
Yasmine M. Abdel Aziz
Mohamed ElgawishMohamed Elgawish
Mohamed Elgawish
MEMarwa Elewa
Marwa Elewa
AYAsmaa yassen
Asmaa yassen
MSMohamed M. Said
Mohamed M. Said
Dual targeting of epidermal growth factor receptor (EGFR) and human EGFR-related receptor 2 (HER2) is a proven approach for the treatment of lung cancer. With the aim of discovering effective dual EGFR/HER2 inhibitors targeting non-small cell lung cancer cell line H1299, three series of thieno[2,3-d][1,2,3]triazine and acetamide derivatives were designed, synthesized, and biologically evaluated. The synthesized compounds displayed IC50 values ranging from 12 to 54 nM against H1299, which were superior to that of gefitinib (2) at 40 µM. Of the synthesized compounds, 2-(1H-pyrazolo[3,4-b]pyridin-3-ylamino)-N-(3-cyano4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)acetamide (21a) achieved the highest in vitro cytotoxic activity against H1299, with an IC50 value of 12.5 nM in situ, and 0.47 and 0.14 nM against EGFR and HER2, respectively, values comparable to the IC50 of the approved drug imatinib (1). Our synthesized compounds were promising, demonstrating high selectivity and affinity for EGFR/HER2, especially the hinge region forming a hydrophobic pocket, which was mediated by hydrogen bonding as well as hydrophobic and electrostatic interactions, as indicated by molecular modeling. Moreover, the designed compounds showed good affinity for T790M EGFR, one of the main mutants resulting in acquired drug resistance. Furthermore, both pharmacokinetic and physicochemical properties of the designed compounds were within the appropriate range for human usage as predicted by the in Silico ADME study. The designed compound (21a) might serve as an encouraging lead compound for the discovery of promising anti-lung cancer agents targeting EGFR/HER2.

2 January 2020 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
REranza elrayess
ranza elrayess
YAYasmine M. Abdel Aziz
Yasmine M. Abdel Aziz
Mohamed ElgawishMohamed Elgawish
Mohamed Elgawish
MEMarwa Elewa
Marwa Elewa
HEHosam A. Elshihawy
Hosam A. Elshihawy
MSMohamed M. Said
Mohamed M. Said

1 June 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MSManar G. Salem
Manar G. Salem
YAYasmine M. Abdel Aziz
Yasmine M. Abdel Aziz
MEMarwa Elewa
Marwa Elewa
MNMohamed S. Nafie
Mohamed S. Nafie
HEHosam A. Elshihawy
Hosam A. Elshihawy
MSMohamed M. Said
Mohamed M. Said